Protein aggregation can be a major problem in the manufacturing of new biopharmaceuticals and there is a desirability for development of techniques that can predict the behaviour of new biopharmaceuticals early on in the development process. A technique that can be used to predict aggregation is self-interaction chromatography that is used to determine the second virial coefficient, B 22 , but one of the limitations includes the need to immobilise every protein of interest. In this study a related technique, cross interaction chromatography (CIC), is evaluated which overcomes this limitation. Three antibodies were studied across a range of NaCl concentrations with each antibody being studied as both a mobile phase and as the stationary phase -in total 6 different stationary-mobile phase combinations. The B 22 values obtained for all three proteins correlated strongly with the B 23 results obtained for the same protein in the mobile phase, and were significantly independent of the protein immobilised on the stationary phase. This observation allows the use of pre-prepared columns with known immobilised model proteins such as a polyclonal antibody or mAb, with other unknown monoclonal antibodies in the mobile phase. Preliminary experiments using a series of known immobilised mAbs columns with an unknown mAb in the mobile phase resulted in at least a 50 fold reduction in the amount of unknown protein needed and a rapid semi-quantitative assessment of aggregation propensity. CIC can speed up the screening process with minimum preparation time and therefore more rapidly be able to identify the aggregation stability of new antibody formulations.
Introduction
Biopharmaceuticals, in particular monoclonal antibodies (mAbs), have been successful therapeutics for a wide range of diseases. However, their tendency to aggregate is a major problem that can compromise the entire production process. Due to the considerable costs arising from mAb therapeutics which do not successfully pass through the development process, the need for more low-cost, rapid screening methods with predictive capabilities which can minimise the risks of failure are critical. It has previously been established that selfinteraction chromatography, SIC, is a useful tool to predict and understand protein-protein interactions in a range of differing solution conditions including crystallisation conditions [1, 2] , protein solubility [3] , protein formulation conditions [4] as well as aggregation propensity [5, 6] . The latter solution conditions are especially critical in the biopharmaceutical industry, as they can occur during any stage of the production process, shipping or storage, and are also directly related to product safety in regards to immunogenic responses in patients [7] .
However, the main limitation of SIC is the immobilisation process that is lengthy, is a non-automated process and consumes the most amount of protein; sometimes 10′s of milligrams, though this limitation can be resolved by different scale-down approaches [8, 9] .
Researchers have studied the viral coefficients for the cross-interactions between two different proteins both to aid and predict the selfinteractions behaviour, but also to explicitly understand the interactions between different proteins. Many techniques are problematic when used for measuring cross-interactions between different proteins, as they cannot measure these cross-interactions directly. These methods used to determine the cross-interactions for proteins prior to the advent of self-interaction chromatography include membrane osmometry [10, 11] , static light scattering (SLS) [12] , size-exclusion chromatography [13] , sedimentation equilibrium [14] , fluorescence depolarisation [15] and turbidity methods [16] . However, of these studies, only membrane osmometry [10, 11] determined osmotic second virial cross coefficients. This method is complex as firstly the relevant properties of the individual proteins had to be measured and then the properties of the mixture at a known composition are determined. Cross-interactions were also measured by SLS, although the data was interpreted with a chemical association model rather than via virial coefficients [17] .
The use of cross-interaction chromatography (CIC) will make it possible to estimate both the interactions between the same two proteins, effectively SIC with a B 22 determination, as well as the osmotic second virial cross coefficient, B 23 , for a series of other proteins, in a single set of experimental measurements. CIC also has the same advantage as SIC in terms of the amount of protein needed for a B 23 measurement in comparison to membrane osmometry and static light scattering [18] typically being 50 times lower. CIC was first performed by Tessier et al. [18] and Teske et al. [19] for lysozyme and BSA (both), lysozyme and α-chymotrypsinogen [18] and lysozyme and ovalbumin [19] . After these first two studies, CIC has been used to predict the precipitation behaviour of protein mixtures that could play an important role in protein separations [20] . Later Jacobs et al. [21] used cross-interaction CIC to predict the solubility of the protein solution mixtures. In a similar way, Mehta et al. [22] used CIC to predict solubility, but specifically between binary protein mixtures using the proteins lysozyme and ovalbumin. In this study it was found that there was a linear correlation between B 23 and the slope of lysozyme solubility versus albumin, which they explained using a preferential interaction theory.
Levy et al. [23] have been applying CIC to characterise the interactions between host cell proteins (HCPs) and mAbs so as to provide insights into how the downstream process could be improved. Quigley and Williams [24] continued with the development of CIC into Similar Interaction Chromatography (SimIC), a screening tool to predict B 33 values (the virial coefficient of the second protein) by knowing B 22 (virial coefficient of the first protein) and B 23 (the second virial cross coefficient). In their paper they investigated lysozyme, catalase, lactoferrin and concanavalin A, with B 23 and B 22 values simply being related through an arithmetic mean approximation: (1)
The advantage of using CIC for the prediction of a B 33 or B 22 values is the scope to develop a very fast screening tool that would further decrease the amount of protein used. From using a few mg in SIC studies, it could now be decreased to typically 10-20 μg per injection. It would also be possible to remove the need of immobilising every single protein to be studied and only use a small number of standard protein immobilised columns for which B 22 values have already been well established. These improvements could lead to cost and time savings within the biopharmaceutical industry which would make CIC an attractive tool to use. No technique other than CIC could make such a prediction due to CIC's ability to determine interactions in a single measurement with one or more reference columns.
This study is first focusing on evaluating the effectiveness of CIC as a screening tool to predict B 33 for therapeutic antibodies using different immobilised columns including other mAb columns and a pIgG column. Unlike other reported studies, here the B 22 and B 23 /B 32 values are directly compared and the most accurate methods to predict B 33 are established. Secondly, this paper aims to develop CIC as a screening method to understand protein behaviour by avoiding the immobilisation process and therefore requiring only micrograms of protein.
Materials and methods

Materials
The experiments were performed with a polyclonal IgG (pIgG) from human serum (I4506, Sigma Aldrich) and two monoclonal antibodies, one of IgG1 type (mAb A) and one of IgG4 type (mAb B) both only partially purified. Both mAbs used were purified using Protein A, thereafter inactivated using a viral inactivation step at pH 3.6 and were then brought up to pH 5.0 in phosphate buffer, in which they were stored in prior to use. Additionally, chromatographic injections were performed with a partially purified mAb referred to as mAb X prepared in a similar way. Dibasic and monobasic sodium phosphate dihydrate, sodium acetate trihydrate, acetic acid (75%), sodium chloride, glutaraldehyde (Grade 1, 25%), Toyopearl AF-Tresyl-650 M (814471) were all purchased from Sigma-Aldrich (ACS grade). The water used for preparing the buffer solutions was ultrapure deionised Milli-Q water (resistivity 18.2 mΩ) (Merck Millipore). The pH of the solutions were measured with a Mettler Toledo SevenCompact TM benchtop pH meter and checked that they were within 0.05 pH units from the desired pH; drops of NaOH and HCl were used to correct the pH. Before using the buffer solutions, all solutions were all filtered and degassed using a vacuum filtration system with a 1 l reservoir and a 0.45 µm PES filters in order to remove particulates present before CIC analysis.
Immobilisation
The immobilisation procedure for both mAbs and the pIgG were performed using the same experimental recipe using Toyopearl AFTresyl particles with glutaraldehyde as a cross-linker. 200 mg of Toyopearl AF-Tresyl was weighed up and activated with 600 µl of glutaraldehyde and washed with at least 60 ml of purified water. Around 22 mg of the protein were mixed with 20 mM sodium phosphate pH 7.0 with 0.3 M NaCl to make up a 3 ml solution. The proteins were added to the activated particles and a duplicate 0 h sample was taken. Afterwards, the protein-particle solution was allowed to react overnight on a roller mixer. The next day the final samples were taken and all the samples concentrations were measured using UV/Vis spectroscopy at 280 nm using a Nanodrop 2000 (ThermoFisher Scientific). The amount of protein immobilised on the column was calculated from a mass balance approach. The amount of protein remaining in the supernatant after the immobilisation procedure was subtracted from the initial amount of protein used in the experiment. It was found that > 98% of protein had been immobilised on the column, which corresponded to a surface coverage of around 39% ± 1% according to the surface coverage definition in Tessier et al. [25] .
Column packing and LC experiments
The immobilised protein particles were slurry packed into an Omnifit benchmark column (6.6 × 100 mm) with one fixed and one adjustable end piece. After column packing the column was washed with the same buffer that was used for the immobilisation on an ÄKTA Explorer system (GE Healthcare) at 5 ml/min for at least 10 column volumes. The wash solution was also analysed using a UV/Vis spectrometer at 280 nm to verify that no protein had eluted off the column. After the wash the chromatography bed had settled completely, and the adjustable column end piece could be set into its final position. The bed height for all columns was 2 cm, which gave a column volume of approximately 0.68 ml for each column.
The CIC experiments were run on a Waters Alliance HPLC System, consisting of quaternary pumping system, autosampler, a UV detector and a degasser. Before the run was started the column was equilibrated with the same buffer until the detector baseline stabilised. The experimental runs were started with an acetone injection for a dead volume determination before the protein samples were injected.
Determination of the Osmotic Second Virial Cross Coefficient and the Osmotic Second Cross Virial Coefficient
In this work both the B 22 and the B 23 of the proteins were determined. B 22 was determined by the following equation [25] using the established method:
where
N A is Avogadro's number and M W is the molecular weight of the protein. B HS is the excluded volume or hard-sphere contribution and denotes the molecular volume of the 4 protein molecules [26] . ρ s represents the total number of immobilised molecules per unit area. ϕ is the phase ratio defined as the total surface available to the mobile phase protein and were interpolated from DePhillips and Lenhoff [27] . k′ is the chromatographic retention factor, incorporating the retention volume of the protein V P and dead volume, V 0 , calculated by injecting protein on a dead column without interactions as described by Hedberg et al. [28] .
The data exported from each run were analysed according to the centre of mass or first moment retention volume based on previous work [29] to reflect heterogeneity of protein solution interactions.
All of the antibodies were assumed to have approximately the same surface volume, diameter and phase ratio. The only minor difference between the antibodies was the molecular weight that for mAb A was taken as 144.5 kDa, for mAb B taken as 145 kDa and for pIgG taken as 150 kDa.
B 23 can be defined as:
[ ]
where r 1 and r 2 are the radii of the two proteins. In a similar way to the determination of B 22 , B 23 also needs a pre-factor of
for the units to be in the correct format of ml mol/g 2 . However, as the B HS term is now the average between the two proteins, the molecular weight also needs to be considered in the pre-factor
where M W1 and M W2 are the respective molecular weights of the two proteins.
Results and discussion
B 22 data
Before any CIC experiments were performed, B 22 values were determined using self-interaction chromatography for all proteins involved in the study. Fig. 1 shows the B 22 values for two monoclonal antibodies and the polyclonal IgG as a function of salt concentration with a sodium acetate buffer at pH 4.0. This specific buffer pH was used as it was observed that the B 22 values clearly decreased with increasing ionic strength. It can be seen that all the proteins have decreasing B 22 values for increasing NaCl concentrations (0.005-0.6 M). When the pH was higher than 4 the differences were less and whilst at pH 6 the impact of NaCl was minimal, and the proteins in general exhibited no net interactions for all conditions. At pH 4 all the IgGs observe more or less strong positive charges and in the presence of increasing ionic strength can create critical additional charges within the protein that may lead to unfolding of the IgG and aggregation. Therefore, pH 4 was chosen as a suitable pH to study using CIC as the interactions vary from weakly repulsive to strongly attractive. Several processing conditions also include low pH or high salt concentrations making this a relevant choice for estimating the process stability of the IgGs.
In Fig. 1 it is observed that mAb A was the protein that demonstrated the most significant decrease in B 22 with ionic strength, with a decrease of greater than 1 × 10 −4 ml mol/g 2 for each addition of 100 mM NaCl. mAb B had the second most significant decrease in B 22 with ionic strength, with a decrease of approximately 0.5 × 10 −4 ml mol/g 2 for each addition of 100 mM NaCl. The impact of ionic strength on pIgG is the smallest with an average decrease of only 0.183 × 10 −4 ml mol/g 2 for each 100 mM NaCl, the highest value of 0.5 × 10 −4 ml mol/g 2 and the lowest value −0.6 × 10 −4 ml mol/g 2 .
B 22 and B 23 data
The B 22 data and the B 23 data are presented in terms of the immobilised columns used. Firstly all protein mobile phase injections were performed on the mAb A immobilised column, then the mAb B immobilised column and finally the pIgG immobilised column. Figs. 2-4 , it can be clearly seen that the mobile phase protein selected for study has a dominant impact on the B 22 or B 23 values determined compared to the specific column studied.
SimIC method evaluation
In Fig. 5 22 and B 33 from different proteins. To easily display the evaluation of the SimIC framework, the two-protein combination are given the same colour scheme in Fig. 5 . If the SimIC approach works all the data points with the same colour would show a similar value, which is clearly not the case here. The only combination where this is the case would be for mAb B and pIgG (displayed in green) at lower ionic strengths. We assume that the only reason why these values were relatively similar is because these protein combinations under these conditions resulted in a low level of net interactions. If these interactions are very different e.g. strongly attractive and weakly repulsive like the mAb A and pIgG combination, this is clearly not the case. There it can be concluded that the SimIC approach does not work in general.
The previous success of the SimIC approach was for proteins of different sizes [24] . This success is because the molecular weight has a significant impact on the B 22 values in Eq. (2) and the value of both proteins' molecular weight will be combined in the calculation of B 23 . In order to test how further evaluate the SimIC framework, it was tested for 4 different theoretical scenarios, one scenario with repulsive interactions, two with attractive interactions (weak and strong) and finally one with no net interactions (neither attractive nor repulsive). These have been defined as different percentages of the dead volume, 80% for the repulsive, 125% and 200% for the attractive and equal to the dead volume for the one with no net interactions. The dead volume is however different for the two proteins due to the size of the protein [28] , hence the results will not always lie as expected in between the B 22 and B 33 data. To test these theoretical scenarios we have to assume that all the protein combinations will display only these four different retention volumes in both their self-and cross-interactions.
In Table 1 it can be seen that for almost all the cases the predicted SimIC B 23 (or B 32 ) is similar to the actual B 23 and B 32 assuming that the self-and cross-interactions have the same retention volumes. In this case there is only one example that is really out of the range for the SimIC prediction, the mAb mobile phase injections on a lysozyme column. However, realistically the retention volumes for self-and crossinteractions are not always the same in real experimental measurements. The take home message from this Table is that the SimIC framework will seem to 'predict' the B 23 value in 90% of all cases plainly because of the different sizes of the proteins that are averaged both in the SimIC equation and the B 23 calculation. As can be seen Fig. 5 SimIC does not work when the proteins are the same size. Therefore, tests on proteins of the same molecular size, as in this study, have highlighted this intrinsic flaw in the framework. In general it was seen clearly that by using the protein of interest in the mobile phase it can serve as an sound estimation of the B 22 value. However, in the case of mAb A, this Figure shows that the columns the protein is injected on still have a minor impact. The B 22 values for mAb A resulting from SIC is the least negative while the B 23 values from CIC are more negative. In this case the pIgG column data shows the strongest negative B 23 values. In all cases it can be seen that the B 23 values are more negative than the B 22 values, which means that CIC is increasing the interactions for a certain protein. For mAb B however, the attractive self-interactions are generally stronger than any cross-interactions. In the case of pIgG there were no distinct differences observed between the columns' performance. The greatest difference observed between B 22 and B 23 values is 1.1 × 10 −4 ml mol/g 2 for pIgG as the mobile phase, which is a typical discrepancy that can be found between two different B 22 measurements. Concluding the findings for the three mobile phases the trend seen is slightly different. In the case of mAb A the CIC is enhancing the interactions, in the case of mAb B CIC is reducing the interactions and for pIgG they are mostly unchanged. However, examining the CIC mobile phase data as a prediction for B 22 , the predictions are relatively close to the actual values. In the case for mAb A injections the differences between the columns is 4 × 10 −4 ml mol/g 2 , and for mAb B it is just over 2 × 10 −4 ml mol/g 2 . Even though these differences are notable, the results will still give an indication of the interactions that can be expected between the proteins. These interactions can still be able to give an useful estimation of the B 22 value for predicting stability [6] and therefore could be used as a quick screening technique. Quigley and Williams [24] reported that the differences of the predicted and actual B 23 values could be up to 6 × 10 −4 ml mol/g 2 .
The experimental observation that the mobile phase has the greatest influence on the retention behaviour is consistent with most findings in literature. Tessier et al. [18] found that this observation was the case for certain protein mixtures, such as lysozyme and α-chymotrypsinogen, at selected conditions as these proteins were similar, with little structural change and immobilised in multiple orientations as per the original assumption for SIC [30] . However another important aspect that affected the previous results were the molecular volume of the two proteins that both resulted in different B 22 and B 23 values and the changed assumptions with a reduced excluded volume when smaller proteins immobilised [18] . Due to the IgGs used in this paper this factor is assumed to be negligible. Jacobs et al. [21] showed that the mAb retention behaviour on a polyclonal IgG column correlated well with the solubility measured by ultrafiltration, which indicates that also in this paper it mobile phase played a major role. Overall, a key observation here is that the mobile phase protein dominates the direction and magnitude of the B 22 data for similar proteins.
3.5. Rapid B 33 predictions for an unknown: mAb X Using this method, the B 33 values (or unknown B 22 values) of mAb X were predicted. mAb X is a therapeutic mAb in limited supply, hence insufficient for immobilisation on a column, so was used as a case study for the CIC method. This experiment was used to validate an important assumption, that by observing similar B 23 values across all tested columns, the B 33 could be rapidly estimated for a mAb which had not been immobilised onto a column. Fig. 7 displays the B 23 results for mAb X injected on a mAb A and mAb B column with increasing ionic strengths. Here it can be seen that the differences between the B 23 results reported on the two columns are very minor. In addition mAb X was also injected on a pIgG column with the higher salt concentrations 0. 4 Table 2 it can be concluded that mAb X has approximately no net interactions at 0 M NaCl and slightly negative net interactions at up to 0.6 M. These results indicate very weak interactions with no salt, with weakly attractive interactions at low pH's with high ionic strengths. As mAb X is a successfully validated therapeutic protein with high stability, it can be concluded that the CIC predictions are consistent with the performance expected for a commercial product.
By evaluating the interactions of the target protein with different columns, a relatively narrow estimate of the B 22 value can be determined very rapidly. This is therefore a positive sign that a CIC type method can be used as a rapid screening tool when selecting between many different mAbs or other biopharmaceutical candidates. Future work will investigate in detail the validity of this CIC method for a series of industrial mAb products.
Conclusions
In this paper the cross-interactions for a number of different proteins have been investigated chromatographically to see whether it is possible to predict the B 33 or unknown B 22 values rapidly with small amounts of products. Three antibodies were studied as stationary and as mobile phases using self-and cross-interaction chromatography, across a range of ionic strengths for a fixed pH. It was observed that the B 23 values obtained when the protein was in the mobile phase gave a good estimation of the B 22 values which was significantly independent of the immobilised stationary phase protein. A single case study of a limited supply therapeutic protein, mAb X, was tested by eluting it through the same three immobilised columns. This experiment rapidly generated a narrow range of B 23 values for mAb X. These tests of mAb X gave B 33 Fig. 7 . B 23 values for mAb X mobile phase injected on mAb A and mAb B immobilised columns at different NaCl concentrations (20 mM sodium acetate pH 4.0). values also significantly independent of the column used, and consistent with those obtained for stable commercial proteins. CIC could, with further experimental method development, be used as a rapid screening tool for predicting stability for new therapeutic candidates using micrograms of sample.
